Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation DOI Creative Commons
Yilamujiang Ainiwan,

H. B. Li,

Yongjia Zheng

et al.

Acta Neuropathologica Communications, Journal Year: 2025, Volume and Issue: 13(1)

Published: March 3, 2025

Although successful treatment of papillary craniopharyngiomas (PCPs) with BRAFv600e inhibitors has been reported in clinical trials, studies have shown that approximately 10% PCPs lack the mutation and may not be significantly effective against these tumors. However, no focused specifically on BRAFv600e− PCPs. Spatial transcriptome sequencing was performed calcified PCP tissue to identify novel subtypes cells. The findings were validated via pathological methods 51 samples. Primary cells from patients BRAFv600e+ isolated then injected into brains nude mice stereotactic surgery establish a stable mouse model human-originated PCP. Model treated vemurafenib, BRAF inhibitor, anlotinib, an angiogenesis inhibitor. BRAFv600e−PCP anlotinib phase 1 trial. Changes tumors monitored methods, CT MRI. Most negative for mutation, confirmed vemurafenib significant therapeutic effect verified that, Two participated trial received therapy; their disappeared after 3 months therapy did recur within 24 follow-up stopping treatment. are characterized by calcification do respond inhibitor which effect.

Language: Английский

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation DOI Creative Commons
Yilamujiang Ainiwan,

H. B. Li,

Yongjia Zheng

et al.

Acta Neuropathologica Communications, Journal Year: 2025, Volume and Issue: 13(1)

Published: March 3, 2025

Although successful treatment of papillary craniopharyngiomas (PCPs) with BRAFv600e inhibitors has been reported in clinical trials, studies have shown that approximately 10% PCPs lack the mutation and may not be significantly effective against these tumors. However, no focused specifically on BRAFv600e− PCPs. Spatial transcriptome sequencing was performed calcified PCP tissue to identify novel subtypes cells. The findings were validated via pathological methods 51 samples. Primary cells from patients BRAFv600e+ isolated then injected into brains nude mice stereotactic surgery establish a stable mouse model human-originated PCP. Model treated vemurafenib, BRAF inhibitor, anlotinib, an angiogenesis inhibitor. BRAFv600e−PCP anlotinib phase 1 trial. Changes tumors monitored methods, CT MRI. Most negative for mutation, confirmed vemurafenib significant therapeutic effect verified that, Two participated trial received therapy; their disappeared after 3 months therapy did recur within 24 follow-up stopping treatment. are characterized by calcification do respond inhibitor which effect.

Language: Английский

Citations

0